Advances in Economics, Management and Political Sciences

- The Open Access Proceedings Series for Conferences


Proceedings of the 2023 International Conference on Management Research and Economic Development

Series Vol. 19 , 13 September 2023


Open Access | Article

The Impact Caused by COVID-19 Pandemic on Pfizer Inc. Stock Price: Based on a Counterfactual Framework

Yuchen Tang * 1
1 University of Toronto

* Author to whom correspondence should be addressed.

Advances in Economics, Management and Political Sciences, Vol. 19, 62-67
Published 13 September 2023. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Yuchen Tang. The Impact Caused by COVID-19 Pandemic on Pfizer Inc. Stock Price: Based on a Counterfactual Framework. AEMPS (2023) Vol. 19: 62-67. DOI: 10.54254/2754-1169/19/20230119.

Abstract

As the coronavirus pandemic spreads worldwide, many nations have implemented social distance regulations and quarantine measures to stop the spread of the COVID-19 epidemic. During this period, people's consumption levels dropped all over the world, resulting in a decrease in the capacity of the entire society to produce goods and services. As a result, thousands of workers lost their jobs and numerous manufacturing plants, entertainment companies struggled financially until going out of business. However, the value of some biopharmaceutical firms' shares has climbed rather than fallen due to some of these businesses made great contribution on preventing the spread of the pandemic by developing vaccines and useful medications. In this article, an American multinational pharmaceutical and biotechnology corporation, Pfizer Inc. was selected and daily stock data from February 2009 to December 2022 was extracted. The ARIMA model was applied to forecast the stock price of Pfizer Inc. without the Covid-19 pandemic. This study focuses on comparing the forecasted stock price with actual stock price and explores the possible reasons for this difference.

Keywords

COVID-19 pandemic; forecast stock price; ARIMA model; Pfizer

References

1. M. Ciotti, M. Ciccozzi, A. Terrinoni, W. Jiang, C. Wang & S. Bernardini (2020) The COVID-19 pandemic, Critical Reviews in Clinical Laboratory Sciences, 57:6, 365-388

2. Talevi, D., Socci, V., Carai, M., Carnaghi, G., Faleri, S., Trebbi, E., Bernardo, A. di, Capelli, F., & Pacitti, F. (2020, May 1). Mental health outcomes of the COVID-19 pandemic. Rivista di Psichiatria, vol: 55.

3. N. Donthu, A. Gustafsson, Effects of COVID-19 on business and research, Journal of Business Research, Volume 117, 2020, Pages 284-289

4. R. Padhan, K.P. Prabheesh, The economics of COVID-19 pandemic: A survey, Economic Analysis and Policy, Volume 70, 2021, Pages 220-237

5. M. Mazur, M. Dang, M. Vega, COVID-19 and the march 2020 stock market crash. Evidence from S&P1500, Finance Research Letters, Volume 38, 2021

6. Michelle Llamas. (2022) Pfizer: Company history, Products & Lawsuits, COVID-19 vaccine, https://www.drugwatch.com/manufacturers/pfizer/#sources

7. Hayes Adam. (2022) “Arima Model: Autoregressive Integrated Moving Average.” https://www.investopedia.com/terms/a/autoregressive-integrated-moving-average-arima.asp

8. Wise Bradley. (2020) Time series analysis with Arima: Part 2. https://blogs.cisco.com/analytics-automation/arima2

9. Salvi Jayesh. (2019) Significance of ACF and PACF Plots in Time Series Analysis. https://towardsdatascience.com/significance-of-acf-and-pacf-plots-in-time-series-analysis-2fa11a5d10a8.

10. Commissioner, O. (n.d.). (2021) FDA approves first COVID-19 vaccine. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine

11. Commissioner, O. of the. (n.d.). (2021) Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of covid-19. U.S. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 2023 International Conference on Management Research and Economic Development
ISBN (Print)
978-1-915371-81-2
ISBN (Online)
978-1-915371-82-9
Published Date
13 September 2023
Series
Advances in Economics, Management and Political Sciences
ISSN (Print)
2754-1169
ISSN (Online)
2754-1177
DOI
10.54254/2754-1169/19/20230119
Copyright
13 September 2023
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated